❌

Reading view

Exploration of multi-omics liquid biopsy approaches for multi-cancer early detection: The PROMISE study

Innovation (Camb). 2025 Aug 6;7(1):101076. doi: 10.1016/j.xinn.2025.101076. eCollection 2026 Jan 5.

ABSTRACT

Although circulating cell-free DNA (cfDNA) methylation has emerged as the mainstream approach in multi-cancer detection blood tests (MCDBTs), the potential of integrating proteins and mutations, to enhance its performance remains unclear. The PROMISE study (NCT04972201) was conducted to investigate the feasibility of a multi-omics integration strategy in MCDBTs across nine types of cancers in head and neck (excluding nasopharynx), esophagus, lung, stomach, liver, biliary tract, pancreas, colorectum, and ovary. Blood samples were prospectively collected from 1,706 participants (840 non-cancer; 866 cancer) and then randomly divided into training and validation sets. The complementarity between various omics were investigated, and specific omics features were carefully selected for further multimodal model construction. The methylation-based classifier outperformed both the mutation-based and protein-based classifiers. As 95.0% of cancer cases detected by the mutation-based classifier were simultaneously identified by the methylation-based classifier, while 14.0% of the protein-positive samples were missed, protein markers may provide complementary value to the methylation-based classifier. Compared with the methylation-based classifier, the multimodal classifier combining methylation and protein features exhibited an improved sensitivity of 75.1% (95% confidence interval [CI], 69.3%-80.3%) at the same specificity of 98.8% with the accuracy of top predicted origin (TPO1) of 73.1% (95% CI, 66.2%-79.2%). Notably, the TPO1 accuracy reached 100% in liver and ovarian cancers with negative results of the methylation-based classifier. Collectively, these data suggest that the integration of protein markers in the multimodal classifier can offer additional benefits to the methylation-based classifier, particularly in identifying liver and ovarian cancers.

PMID:41737326 | PMC:PMC12925926 | DOI:10.1016/j.xinn.2025.101076

  •  

Beyond Monolithic Architectures: A Multi-Agent Search and Knowledge Optimization Framework for Agentic Search

arXiv:2601.04703v1 Announce Type: new Abstract: Agentic search has emerged as a promising paradigm for complex information seeking by enabling Large Language Models (LLMs) to interleave reasoning with tool use. However, prevailing systems rely on monolithic agents that suffer from structural bottlenecks, including unconstrained reasoning outputs that inflate trajectories, sparse outcome-level rewards that complicate credit assignment, and stochastic search noise that destabilizes learning. To address these challenges, we propose \textbf{M-ASK} (Multi-Agent Search and Knowledge), a framework that explicitly decouples agentic search into two complementary roles: Search Behavior Agents, which plan and execute search actions, and Knowledge Management Agents, which aggregate, filter, and maintain a compact internal context. This decomposition allows each agent to focus on a well-defined subtask and reduces interference between search and context construction. Furthermore, to enable stable coordination, M-ASK employs turn-level rewards to provide granular supervision for both search decisions and knowledge updates. Experiments on multi-hop QA benchmarks demonstrate that M-ASK outperforms strong baselines, achieving not only superior answer accuracy but also significantly more stable training dynamics.\footnote{The source code for M-ASK is available at https://github.com/chenyiqun/M-ASK.}
  •  

A full life cycle biological clock based on routine clinical data and its impact in health and diseases

Nature Medicine, Published online: 27 October 2025; doi:10.1038/s41591-025-04006-w

The biological clock model LifeClock predicts biological age across all life stages from routine clinical data, revealing distinct pediatric and adult disease risk patterns.
  •  
❌